Liarozole (R75251) in hormone-resistant prostate cancer patients

Prostate

Volumn 33, Issue 1, 1997, Pages 26-31

  Dijkman, G A ^a   Fernandez Del Moral, P ^a   Bruynseels, J ^a   De Porre, P ^a   Denis, L ^a   Debruyne, F M J ^a  

^a Ignatius Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIAROZOLE; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRY SKIN; ERYTHEMA; HUMAN; MAJOR CLINICAL STUDY; NAIL DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG RESISTANCE; HORMONES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030823729     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970915)33:1<26::AID-PROS5>3.0.CO;2-7     Document Type: Article

References (30)

1. Parkin DM (ed): "Cancer Incidence in Five Continents," Volume 6, Lyon: International Agency for Research on Cancer 1992.
2. Raghaven D, Lange PH: Endocrine aspects of genito-urinary neoplasia. In Shearman RP (ed.): "Clinical Reproductive Endocrinology," London: Churchill Livingstone, 1985:727-752.
3. Huggins C, Stevens RE IR, Hodges CV: Studies on prostatic cancer II: The effects of castration on advanced prostate carcinoma of the prostate gland. Arch Surg 1941;43:209-223.
4. Kirk D: Prostatic carcinoma. Br Med J 1985;290:875-876.
5. Isaacs JT: New principles in the management of prostate cancer. Therapeutic principles in metastatic prostate cancer. In: Schröder FH, Richards ED (eds): New York: Alan R. Liss, Inc.; 1987: 383-392.
6. Eisenberger MA: Chemotherapy for Advanced Prostate Cancer. 6 Monographs, the Medical Management of Prostate Cancer II, 1991:75-87.
7. Wouters W, Van Dun J, Dillen A, Coene M-C, Cools W, De Coster R: Effects of liarozole, a new antitumoral compound on retinoid acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 1992;52:2841-2846.
8. Van Wauwe J, Van Nyen G, Coene M-C, Stoppie P, Cools W, Goossens J, Borghgraef P, Janssen PAJ: Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992;261:773-779.
9. Lotan R: Mechanisms of action of retinoids. Cancer 1986;38:13-26.
10. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 1992;10:839-864.
11. Lee JS, Neuman RA, Lippman SM, Huber MN, Minot T, Raber MN, Krakhoff IH, Hong WK: Phase I evaluation of all-transretinoic acid in adults with solid tumors. J Clin Oncol 1993;11: 959-966.
12. Van Heusden J, Borgers M, Ramakers F, Xhonneux B, Wouters W, De Coster R, Smets G: Liarozole potentiates the all trans retinoic acid induced structural remodelling in human breast carcinoma MCF 7 cells in vitro. Eur J Cell Biol 1996;71:89-98.
13. Van Wauwe JP, Coene M-C, Goossens J, Cools W, Montbaliu J: Effects of cytochrome P450 inhibitors on the in vivo metabolism of all-transretinoic acid in rats. J Pharmacol Exp Ther 1990;252: 365-369.
14. Westarp ME, Westarp MP, Bruynseels J, Bollas W, Komheber HH: Oral liarozole as a catabolic inhibitor potently increases retinoic acid in vivo: First experience from an ongoing therapeutic trial in highly malignant primary brain tumors. Onkologie 1993;16:22-25.
15. De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene M-C, Bowden D: Experimental studies with liarozole (R75251): An antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992;43:197-201.
16. Miller VA, Rigas JR, Muindi JRF, Tong WP, Venkatraman E, Kris MG, Warrell RP Jr: Modulation of all-trans-retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1994;34:522-526.
17. Van Ginckel R, De Coster R, Wouters W, Van der Veer R, Goeminne N, Jagers E, Van Cauteren H, Wouters L, Distelmans W, Janssen PAJ: Antitumoral effects of R75251 on the growth of transplantable R3372 prostatic adenocarcinoma in rats. Prostate 1990;16:313-323.
18. Dijkman GA, Van Moorselaar RJA, Van Ginckel R, Van Stratum P, Wouters L, Debruyne FMJ, Schalken JA, De Coster R: Anti-tumoral effects of liarozole in androgen-dependent and 1-independent R3327 Dunning prostate adenocarcinomas. J Urol 1994; 151:217-222.
19. Smets G, Van Ginckel R, Daneels G, Moeremans M, Van Wauwe J, Coene M-C, Ramaekers FCS, Schalken JA, Borgers M, De Coster R: Liarozole, an antitumour drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-transretinoic acid. Prostate 1995;27: 129-140.
20. Isaacs JT, Isaacs WB, Feitz F, Scheres J: Establishment and characterization of seven Dunning prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancer. Prostate 1986;9:261-281.
21. Eisenberger MA: Chemotherapy for prostate carcinoma. Natl Cancer Inst Monogr 1988;7:151-164.
22. Newling DWW, Fossa SD, Tunn UW, Kurth K, de Pauw M, Sylvester R: Mitomycin-C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: The final analysis of the EORTC GU group prospective randomized phase III study (30865). J Urol 1993;150:1840-1844.
23. Murphy GP, Priore RL, Scardino P: Hormone refractory prostate cancer treated with methotrexate, cyclophosphamide and adriamycin, cisplatin plus 5-fluorouracil plus cyclophosphamide: National Prostate Cancer Project randomized trial. Urology 1988;33:33-40.
24. Yagonda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
25. Kozlowski JM, Grayhack JT: Carcinoma of the prostate. In Gillenwater J (eds): "Adult and Pediatric Urology," 3rd ed. 1996: 1679-1689.
26. Catkovic E, Dioz JP, Armand JP, Khoury S (eds): "Handbook of Chemotherapy in Clinical Oncology," Scientific Communication Intl. Ltd., 1993.
27. Raghavan D: Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs. Semin Oncol 1988;15:371-389.
28. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-694.
29. Eisenberger MA, Reyno L, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC, Egorin MJ: Suramin: An active drug for prostate cancer: Interim observations in a phase I trial. JNCI 1993;85:611-621.
30. Dawson NA, Steinberg WD, Figg WD, Tompkins A, Choyke P, Bergan RC, Sartor O, Cooper MR, Sausville EA, Reed E, Myers CE: A phase II trial of leuprolide, flutamide and suramin in previously untreated metastatic prostate cancer. Proceedings of ASCO 31th Annual Meeting, May 20-23 Los Angeles, 1995;14: 617.